标题
Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
作者
关键词
Autoinjector, Clinically isolated syndrome, Clinical trial, Disease-modifying therapy, Multiple sclerosis, Neurology, Relapsing–remitting, Secondary-progressive, Safety, Tolerability
出版物
ADVANCES IN THERAPY
Volume 31, Issue 9, Pages 915-931
出版商
Springer Nature
发表日期
2014-09-02
DOI
10.1007/s12325-014-0149-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
- (2014) Dean M. Wingerchuk et al. MAYO CLINIC PROCEEDINGS
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform
- (2014) Vilija G. Jokubaitis et al. PLoS One
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
- (2013) Claudio Gobbi et al. BMC Neurology
- Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
- (2013) Neetu Agashivala et al. BMC Neurology
- BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
- (2013) Robert J. Fox et al. CURRENT MEDICAL RESEARCH AND OPINION
- Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
- (2013) G. Edan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Immune Therapy of Multiple Sclerosis - Future Strategies
- (2012) Sven G. Meuth et al. CURRENT PHARMACEUTICAL DESIGN
- Survival in MS
- (2012) D.S. Goodin et al. NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
- (2012) Douglas S Goodin et al. BMJ Open
- Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
- (2012) Paul I. Creeke et al. Therapeutic Advances in Neurological Disorders
- Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
- (2011) Douglas S Goodin et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis — Results of the BetaPlus observational cohort study
- (2011) Carlo Pozzilli et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial
- (2011) Douglas S Goodin et al. Multiple Sclerosis Journal
- Interferon -1b and glatiramer acetate effects on permanent black hole evolution
- (2011) M. Filippi et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial
- (2010) G. C. Ebers et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cross-sectional study assessing long-term safety of interferon- -1b for relapsing-remitting MS
- (2010) A. T. Reder et al. NEUROLOGY
- Improving Compliance with Interferon-β Therapy in Patients with Multiple Sclerosis
- (2009) Emilio Portaccio et al. CNS DRUGS
- High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
- (2009) Hans-Peter Hartung EXPERT OPINION ON PHARMACOTHERAPY
- New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate
- (2009) D Cadavid et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
- (2009) G Comi et al. LANCET
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study
- (2009) D. Cadavid et al. NEUROLOGY
- Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period
- (2008) Alessandra Lugaresi et al. CLINICAL NEUROPHARMACOLOGY
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway
- (2008) N Grytten Torkildsen et al. Multiple Sclerosis Journal
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started